Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Myelodysplastic Syndromes 10 Leukemia, Myeloid, Acute 7 Hematologic Neoplasms 7 Leukemia 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Lymphoma, Non-Hodgkin 4 Lymphoma 4 Primary Immunodeficiency Diseases 3 Cytopenia 3 Anemia, Aplastic 3 Thalassemia 2 Osteopetrosis 2 Multiple Myeloma 2 Hemoglobinopathies 2 Fanconi Anemia 2 Anemia, Sickle Cell 2 Anemia, Diamond-Blackfan 2 Anemia 2 Uveal Melanoma 1 Thymoma 1 Thymic epithelial tumor 1 Prostatic Neoplasms 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Hodgkin Disease 1 Hematologic Diseases 1 Graft vs Host Disease 1 Castrate Resistant Prostate Cancer (CRPC) 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

Robotic Surgical Procedures 2 N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 2 pembrolizumab 1 isophosphamide mustard 1 fludarabine 1 atezolizumab 1 anetumab ravtansine 1 Octreotide 1 Imatinib Mesylate 1 Gemcitabine 1 Fentanyl 1 Cyclophosphamide 1 Cisplatin 1 AP 1903 reagent 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Thymoma × AP 1903 reagent × Clear all

NCT07598955 2026-05-20

SELECT-NK-THYM

Beijing Biotech

Phase 1/2 Recruiting

Thymic epithelial tumor, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡